SWEET
Sweeteners and sweetness enhancers: Impact on healthy, obestity, safety and sustainability
♦ Investigador principal: Prof. J. Alfredo Martinez
♦ Coordinador: University of Liverpool
♦ Call: H2020-SFS-2016-2017
Topic: SFS-40-2017
Grant Agreement: 774293
The SWEET project has been designed to:
i) identify and address the barriers and facilitators to the use of sweeteners and sweetness enhancers (S&SEs) and
ii) examine the risks and benefits of using S&SEs to replace sugar in the diet in the contexts of health, obesity, safety and sustainability. Industry experts will integrate technological, health and sweetness databases to provide a platform on which new and emerging S&SEs can be selected for inclusion in food products.
The behavioural and physiological impact of specific S&SEs will be examined in acute and repeated dosing studies and natural population differences (by age, region, gender etc) in sweetness perception established. A sensory profile will be developed and genetic determinants assessed. The core randomised controlled trial will adopt a whole diet approach to examine the impact of prolonged sugar replacement on weight control, appetite and energy intake.
Underlying mechanistic effects of S&SE use, alone and in combination, will be evaluated using the technology platform developed in acute studies.
Outcomes relating to safety and overall health risks will be:
i) measured in acute and chronic studies and
ii) investigated in secondary data (long term interventions, prospective cohorts).
The preferences for and perceptions of S&SEs within European consumers, and the barriers to their acceptance, consumption and use will be determined.
The environmental cost and sustainability of replacing sugar with S&SEs will also be modelled. Consumers will be engaged to inform research design, and stakeholder driven exploitation and impact plans will be developed to communicate and disseminate project objectives and results to:
i) address the role of sweeteners in weight control for target audiences (consumers, health professions, scientists, policy makers, regulators) and
ii) move effective products nearer to market.
A gender action plan will be developed and implemented to promote equity across all research activities.
Overall objective: To examine the barriers & facilitators to the use of sweeteners & sweetness enhancers (S&SEs) & examine the likely risks & benefits of using them to replace sugar in the diet in the context of health, obesity, safety & sustainability.
Sub-objectives:
1. Select new & emerging S&SEs& blends, & through integration of technological expertise produce a range of innovative S&SE containing products of appeal to distinct demographics (e.g. age, region, gender).
2. Develop a platform of measures (e.g self-report, biological, cognitive, consumer questionnaires), including new tools, to examine the impact of replacing dietary sugar with S&SEs& validate against new urinary biomarker assays.
3. Determine the role of individual differences (both behavioural e.g. eating behaviour traits & biological e.g. taste receptor polymorphisms) in shaping food preferences & consumption patterns of distinct populations, & examine biological mechanisms underpinning these.
4. Assess the short term effect of specific S&SEs & blends & the prolonged impact of a whole diet approach on body weight, health, satiety, microbiota, biobehavioural processes & consumer perspectives & preferences.
5. Synthesise evidence from diverse European longitudinal data sets to examine the relationship between habitual S&SE use & obesity, health & safety in key geographic & demographic cohorts.
6. Examine the economic, environmental & social sustainability of replacing sugar with S&SEs across production, supply, consumption & waste (life cycle sustainability assessment) in the context of global supply chains using project case studies.
7. Assess the potential toxicology, allergencity & safety (microbiological, gastrointestinal (G.I.) side effects, microbiota & other adverse effects) of specific novel S&SE combinations & of the whole diet approach.
8. Review the regulatory barriers to innovation & tailor exploitation plans & dissemination accordingly.
Participant Name |
Participant Organisation Name |
Type |
Country |
1. Jason Halford |
University of Liverpool (Co-ordinator) |
RI |
UK (GB) |
2. Anne Raben |
Kobenhavns Universitet |
RI |
Denmark (DK) |
3. Douwina Bosscher |
Cargill R&D Centre Europe |
I |
Belgium (BE) |
4. Alfredo Martinez |
University of Navarra |
RI |
Spain (ES) |
5. Edith Feskens |
Wageningen University |
RI |
Netherlands(NL) |
6. Monique Raats |
University of Surrey |
RI |
UK (GB) |
7. Euan Woodward |
European Association for the Study of Obesity |
NPO |
UK (GB) |
8. Alain Lebail |
Oniris |
RI |
France (FR) |
9. Graham Finlayson |
University of Leeds |
RI |
UK (GB) |
10. Yannis Manios |
Harokopio University |
RI |
Greece (GR) |
11. Lluis Serra |
Fundacio Privada per a la Investigacio Nutricional |
RI |
Spain (ES) |
12. Mark Reed |
University of Newcastle Upon Tyne |
RI |
UK (GB) |
13. George Nychas |
Agricultural University of Athens |
RI |
Greece (GR) |
14. LoicBriand |
InstitutNational de la RechercheAgronomoique |
RI |
France (FR) |
15. Laetitia Gerbe |
Tereos Participations |
I |
France (FR) |
16. Santiago Ortega |
CTAEX |
SME |
Spain (ES) |
17. Martine Laville |
CRNH Rhone-Alpes |
RI |
France (FR) |
18. Torsten Sehlinger |
Mobile Chamber Experts GmbH |
SME |
Germany (DE) |
19. Ellen Blaak |
Universiteit Maastricht |
RI |
Netherlands (NL) |
20. Tony Lam |
Netunion |
SME |
Switzerland (CH) |
21. Helen Claringbould |
Corepage |
SME |
Netherlands (NL) |
22. Marine Boursier |
Vitagora Pole |
NPO |
France (FR) |
23. Stephane Vidry |
International Life Sciences Institute (European Branch) |
SME |
Belgium (BE) |
24. Jasper Scholten |
Blonk Milieu Advies BV |
SME |
Netherlands (NL) |
25. Paul Finglas |
European Food Information Ress AISBL (EUROFIR) |
SME |
Belgium (BE) |
26. Maurizio Notarfonso |
SPREAD EUROPEAN SAFETY GEIE (SPES GEIE) |
NPO |
Italy (IT) |
27. Fottes Panetsos |
Bioiatriki SA |
I |
Greece (GR) |
28. Clare Llewellyn |
University College London |
RI |
UK (GB) |
29. Alicja Szofer-Araya |
European Clinical Research Infrastructure Network |
NPO |
France (FR) |